Alzheimer's Fast Track 2026
Join us for Alzheimer’s Fast Track, November 11-13, 2026, in Washington, D.C.
About Alzheimer’s Fast Track
Learn from experts in the field of Alzheimer’s disease and related dementias at the Alzheimer’s Fast Track workshop. Designed for graduate students, postdoctoral fellows, and other early-career scientists focused on Alzheimer’s disease research, this immersive learning experience will accelerate your knowledge, expertise, and visibility in this exciting field.
2026 Event Details
November 11-13, 2026
Hilton Washington DC National Mall The Wharf
Washington, DC
Official pre-meeting to Society for Neuroscience
Contact researchgrants@brightfocus.org with questions.
Co-Chairs
Timothy Hohman, PhD
Vanderbilt Memory and Alzheimer’s Center
Frank LaFerla, PhD
University of California, Irvine
Cynthia Lemere, PhD
Brigham and Women’s Hospital, Harvard Medical School
Sharyn Rossi, PhD
BrightFocus Foundation
Harry Steinbusch, PhD
Maastricht University,
The Netherlands
Related News & Research Breakthroughs
Article
Breaking News Dispatch: Diversifying the Alzheimer’s Disease Treatment Portfolio
Read the latest research news and findings from the latest international Alzheimer’s conference.
Article
Leqembi At-Home Injectable Now FDA Approved for Starting Alzheimer’s Treatment
The FDA has extended approval for the at-home formulation of Leqembi to include starter, in addition to maintenance, doses, making treatment more accessible.
Press Release
BrightFocus Foundation, Alzheimer's LA Fund New AI-Driven Alzheimer's Research
Early-stage pilot grants aim to accelerate innovation and collaboration in Southern California.
Press Release
BrightFocus Foundation Launches "Let's Talk Alzheimer's" Podcast Featuring Top Experts in Alzheimer's Research
New podcast features world-class scientists and doctors discussing late-breaking Alzheimer’s and dementia research in plain language for families and caregivers.
Article
Can Better Sleep Slow Alzheimer's?
New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way.
Article
FDA Approves Repurposed Anti-Depressant to Treat Alzheimer's-Associated Agitation
Auvelity, developed by Axsome Therapeutics, was approved today by the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease agitation, a common and challenging symptom that affects 40 to 60 percent of people living with Alzheimer’s.